Flublok (Sanofi) is a quadrivalent recombinant seasonal influenza vaccine that contains antigens from two A strains and two B strains specified by the World Health Organization seasonally for influenza vaccination. In the US, the trivalent form of Flublok was approved for use in persons aged 18–49 years in 2013. The quadrivalent form was approved in October 2016 in the US for use in people aged 18 years and older. In the EU, Protein Sciences halted the development of trivalent Flublok to pursue a quadrivalent vaccine in the coming years.
Flublok (recombinant quadrivalent influenza vaccine [QIV]; Sanofi) was the first influenza vaccine manufactured without using the traditional egg-based process, and therefore does not contain any egg proteins. As Flublok does not contain any egg components, this makes it suitable for people with egg allergies.
LIST OF TABLES
6 Table 1: Flublok drug profile
7 Table 2: Approval history of Flublok for seasonal influenza vaccination
8 Table 3: Late-phase trials of Flublok for seasonal influenza vaccination
9 Table 4: Flublok for seasonal influenza – SWOT analysis
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.